Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...
Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for REGENXBIO in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now expects that the ...
Leber congenital amaurosis (LCA) and early-onset severe retinal dystrophy (EOSRD) are both genetically and phenotypically heterogeneous, and characterised clinically by severe congenital/early infancy ...
James initiated coverage on Regenxbio Inc . (NASDAQ:RGNX), bestowing an Outperform rating and setting a price target of $27.00 for the biotechnology company's shares. The firm's endorsement comes with ...
Background/Aim To provide a comprehensive multimodal retinal imaging characterisation of patients with North Carolina macular dystrophy (NCMD). Methods Clinical evaluation and retinal imaging in six ...
Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings ...
It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback